Stock listing
BOATS:ACRV Acrivon Therapeutics, Inc. Stock
US listing (BOATS) of Acrivon Therapeutics, Inc. · home listing NASDAQ:ACRV
Follow Acrivon Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ACRV
$1.74 USD +0.07 (+4.2%)
Close on Nov 4, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ACRV
- Day range
- $1.66 – $1.77 USDNov 4, 2026
- Volume
- 127,768 sharesNov 4, 2026
- Market cap
- $74.56M USDAt the close on Nov 4, 2026 · price × 42.85M shares outstanding
- 52-week range
- $1.27 – $3.56 USDLowest and highest trades, Nov 5, 2025 – Nov 4, 2026
- Traded on an average day
- $562,801 USDMedian day 222,639 shares · last 3 months, Aug 4, 2026 – Nov 4, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACRV · Home | $1.74 USD | +0.07 (+4.2%) | 127,768 | $1.69 | $1.77 | $1.655 | $1.67 | Close on Nov 4, 2026 |
Daily closes
Last 3 months, Aug 4, 2026 – Nov 4, 2026 · NASDAQ:ACRV · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.74 | +0.07 | +4.2% | $1.69 | $1.77 | $1.655 | 127,768 | |
| $1.67 | +0.06 | +3.7% | $1.61 | $1.67 | $1.61 | 133,679 | |
| $1.61 | -0.05 | -3.0% | $1.66 | $1.707 | $1.58 | 228,177 | |
| $1.66 | -0.10 | -5.7% | $1.74 | $1.76 | $1.65 | 165,284 | |
| $1.76 | -0.03 | -1.7% | $1.79 | $1.85 | $1.71 | 110,500 | |
| $1.79 | +0.05 | +2.9% | $1.69 | $1.79 | $1.678 | 132,227 | |
| $1.74 | +0.02 | +1.2% | $1.73 | $1.78 | $1.63 | 168,358 | |
| $1.72 | -0.01 | -0.6% | $1.74 | $1.77 | $1.69 | 259,073 | |
| $1.73 | -0.03 | -1.7% | $1.76 | $1.82 | $1.68 | 108,071 | |
| $1.76 | -0.065 | -3.6% | $1.84 | $1.86 | $1.72 | 90,186 | |
| $1.825 | +0.03 | +1.7% | $1.80 | $1.88 | $1.80 | 159,072 | |
| $1.795 | +0.105 | +6.2% | $1.78 | $1.82 | $1.75 | 184,695 | |
| $1.69 | +0.05 | +3.0% | $1.68 | $1.74 | $1.63 | 122,219 | |
| $1.64 | -0.12 | -6.8% | $1.75 | $1.77 | $1.63 | 266,379 | |
| $1.76 | +0.04 | +2.3% | $1.74 | $1.80 | $1.71 | 114,477 | |
| $1.72 | -0.03 | -1.7% | $1.73 | $1.81 | $1.70 | 215,810 | |
| $1.75 | -0.15 | -7.9% | $1.86 | $1.872 | $1.74 | 477,200 | |
| $1.90 | -0.01 | -0.5% | $1.91 | $1.929 | $1.87 | 140,200 | |
| $1.91 | +0.04 | +2.1% | $1.88 | $1.955 | $1.862 | 192,000 | |
| $1.87 | -0.01 | -0.5% | $1.89 | $1.905 | $1.78 | 419,700 | |
| $1.88 | +0.02 | +1.1% | $1.85 | $1.913 | $1.82 | 283,500 | |
| $1.86 | -0.12 | -6.1% | $2.00 | $2.07 | $1.85 | 158,300 | |
| $1.98 | -0.01 | -0.5% | $1.99 | $2.035 | $1.91 | 402,100 | |
| $1.99 | -0.02 | -1.0% | $2.05 | $2.06 | $1.99 | 205,100 | |
| $2.01 | -0.04 | -2.0% | $2.02 | $2.12 | $2.00 | 316,900 | |
| $2.05 | -0.03 | -1.4% | $2.09 | $2.16 | $2.04 | 175,100 | |
| $2.08 | +0.02 | +1.0% | $2.05 | $2.12 | $2.05 | 132,500 | |
| $2.06 | -0.04 | -1.9% | $2.08 | $2.12 | $2.025 | 231,000 | |
| $2.10 | -0.02 | -0.9% | $2.12 | $2.13 | $2.07 | 181,900 | |
| $2.12 | +0.06 | +2.9% | $2.10 | $2.15 | $2.04 | 316,700 | |
| $2.06 | -0.09 | -4.2% | $2.14 | $2.17 | $2.025 | 433,200 | |
| $2.15 | +0.14 | +7.0% | $2.04 | $2.24 | $2.01 | 572,500 | |
| $2.01 | +0.16 | +8.6% | $1.89 | $2.025 | $1.871 | 333,900 | |
| $1.85 | +0.15 | +8.8% | $1.71 | $1.895 | $1.69 | 477,400 | |
| $1.70 | 0.00 | 0.0% | $1.74 | $1.77 | $1.67 | 463,700 | |
| $1.70 | -0.13 | -7.1% | $1.85 | $1.90 | $1.695 | 764,300 | |
| $1.83 | -0.13 | -6.6% | $1.97 | $1.975 | $1.805 | 303,700 | |
| $1.96 | -0.04 | -2.0% | $1.98 | $1.99 | $1.94 | 208,200 | |
| $2.00 | -0.04 | -2.0% | $2.05 | $2.06 | $1.95 | 461,600 | |
| $2.04 | +0.05 | +2.5% | $2.03 | $2.06 | $1.96 | 323,900 | |
| $1.99 | -0.11 | -5.2% | $2.10 | $2.17 | $1.99 | 238,800 | |
| $2.10 | -0.03 | -1.4% | $2.13 | $2.175 | $2.07 | 126,400 | |
| $2.13 | +0.07 | +3.4% | $2.06 | $2.14 | $2.055 | 184,500 | |
| $2.06 | -0.09 | -4.2% | $2.15 | $2.15 | $2.045 | 118,800 | |
| $2.15 | +0.08 | +3.9% | $2.07 | $2.20 | $2.05 | 131,100 | |
| $2.07 | -0.02 | -1.0% | $2.07 | $2.125 | $2.025 | 356,500 | |
| $2.09 | +0.03 | +1.5% | $2.04 | $2.11 | $2.021 | 160,100 | |
| $2.06 | -0.09 | -4.2% | $2.16 | $2.19 | $2.05 | 217,100 | |
| $2.15 | +0.07 | +3.4% | $2.11 | $2.20 | $2.08 | 188,300 | |
| $2.08 | -0.10 | -4.6% | $2.17 | $2.19 | $2.08 | 160,100 | |
| $2.18 | -0.02 | -0.9% | $2.19 | $2.255 | $2.17 | 242,700 | |
| $2.20 | -0.01 | -0.5% | $2.19 | $2.225 | $2.06 | 171,000 | |
| $2.21 | +0.01 | +0.5% | $2.21 | $2.31 | $2.18 | 360,800 | |
| $2.20 | -0.19 | -7.9% | $2.33 | $2.37 | $2.17 | 499,200 | |
| $2.39 | +0.34 | +16.6% | $2.06 | $2.39 | $2.06 | 731,500 | |
| $2.05 | 0.00 | 0.0% | $2.05 | $2.065 | $1.97 | 336,400 | |
| $2.05 | +0.10 | +5.1% | $2.11 | $2.14 | $1.96 | 1,501,300 | |
| $1.95 | +0.10 | +5.4% | $1.90 | $1.99 | $1.85 | 758,100 | |
| $1.85 | +0.13 | +7.6% | $1.73 | $1.90 | $1.704 | 422,300 | |
| $1.72 | -0.01 | -0.6% | $1.75 | $1.75 | $1.70 | 152,100 | |
| $1.73 | -0.01 | -0.6% | $1.78 | $1.78 | $1.69 | 164,500 | |
| $1.74 | +0.01 | +0.6% | $1.77 | $1.78 | $1.73 | 228,900 | |
| $1.73 | +0.04 | +2.4% | $1.73 | $1.76 | $1.71 | 302,100 | |
| $1.69 | +0.05 | +3.0% | $1.62 | $1.69 | $1.602 | 316,200 | |
| $1.64 | +0.08 | +5.1% | $1.61 | $1.65 | $1.59 | 318,800 | |
| $1.56 | 0.00 | 0.0% | $1.57 | $1.61 | $1.555 | 184,300 |
- Ticker
- BOATS:ACRV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 50 slides
Latest news
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
Oct 29, 2026
Closed $1.76 (-1.7%) on Oct 29, 2026
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
Oct 20, 2026
Closed $1.80 (+6.2%) on Oct 20, 2026
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
Sep 2, 2026
Closed $2.15 (+3.9%) on Sep 2, 2026
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Aug 31, 2026
Closed $2.09 (+1.5%) on Aug 31, 2026
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
Aug 12, 2026
Closed $1.85 (+7.6%) on Aug 13, 2026
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Aug 5, 2026
Closed $1.64 (+5.1%) on Aug 5, 2026
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Jul 21, 2026
Closed $1.68 (-4.0%) on Jul 22, 2026
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
May 21, 2026
Closed $1.79 (+1.7%) on May 21, 2026
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
May 13, 2026
Closed $1.92 (0.0%) on May 14, 2026
Decks
Investor Presentation (September 2026)
Investor deck · 50 slides · September 2026
Technical Presentation (July 2026)
Technical · 15 slides · July 2026
Investor Presentation (March 2026)
Investor deck · 48 slides · Mar 19, 2026
TD Cowen Healthcare Conference 2026
Conference · 9 slides · Mar 2, 2026
Acrivon Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 72 in all · newest Nov 4, 2026 · oldest 2023
- Decks
- 16 decks · latest September 2026
Where Acrivon Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACRV · Home listing | NASDAQ | United States | USD |
| BOATS:ACRV · This page | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Acrivon Therapeutics, Inc.